ArticleJournal of dental sciences2026
Systematic evaluation of genetic polymorphisms in carcinogen metabolizing enzymes associated with the risk of oral potentially malignant disorders occurrence.
Article in Journal of dental sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The impact of genetic polymorphisms in xenobiotic-metabolizing enzymes and the risk of oral cancer: a critical review.Medical oncology (Northwood, London, England) · 2026Review
- Breast cancer risk genes affecting individual radiosensitivity.Scientific reports · 2026Article
- Systematic evaluation of genetic polymorphisms in carcinogen metabolizing enzymes associated with oral potentially malignant disorders progression to oral cancer risk.Journal of dental sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Accumulated studies investigate the association of single-nucleotide polymorphisms (SNPs) in carcinogen metabolizing enzymes with oral potentially malignant disorders (OPMD) risk. However, these results were inconsistent and conflicting. The purpose of this pooled analysis was to systematically evaluate the associations of SNPs in 6 enzymes (CYP1A1, CYP2E1, GSTM1, GSTM3, GSTT1 and GSTP1) with risk of OPMD occurrence. Materials and methods: A systematic evaluation was performed to identify all eligible case ndash;control studies on the association between SNPs in 6 enzymes and OPMD onset. Odds ratios (ORs) and 95 % confidence intervals (CIs) were pooled to estimate association strength. Results: A significant association of CYP2E1 PstI polymorphism with OPMD was found (OR, 1.46; 95%CI, 1.07-2.00) in 430 cases and 818 health controls. A significant association of GSTM1 null genotype with OPMD, especially oral leukoplakia, was found (OR, 1.72; 95%CI, 1.24-2.37) in 2228 cases and 4425 controls. A significant association of GSTT1 null genotype with OPMD, particularly oral submucous fibrosis, was found (OR, 1.50; 95%CI, 1.01-2.22) in 1798 cases and 3934 controls. A marginally significant association of GSTM3 polymorphism with OPMD was found (OR, 1.41; 95%CI, 1.00-1.98) in 321 cases and 622 controls. There was no significant association of polymorphisms in CYP1A1, CYP2E1 RsaI variant, and GSTP1 with OPMD. Conclusion: This analysis for the first time investigated SNPs in carcinogen metabolizing enzymes with OPMD, suggesting that polymorphisms in CYP2E1 PstI, GSTM1, GSTM3 and GSTT1 play roles in OPMD occurrence and highlighting their potential in risk stratification and early detection strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.